Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution
Portfolio Pulse from Benzinga Newsdesk
Grifols has received FDA approval for its fibrin sealant solution to treat surgical bleeding in pediatric patients in the U.S. This expands the use of their product, already approved in Europe, and is part of a collaboration with Johnson & Johnson MedTech.
October 29, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Grifols received FDA approval for its fibrin sealant solution for pediatric use in the U.S., potentially boosting its market presence and sales.
The FDA approval allows Grifols to expand its product offering in the U.S. market, potentially increasing sales and market share. The approval for pediatric use opens a new segment, enhancing the company's growth prospects.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Johnson & Johnson MedTech, in collaboration with Grifols, will distribute the newly FDA-approved fibrin sealant solution in the U.S., potentially increasing its product offerings and market reach.
The strategic collaboration with Grifols allows Johnson & Johnson MedTech to expand its product offerings in the U.S. market, potentially increasing its market reach and sales through the distribution of the newly approved product.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 70